Drug Profile
K 103 IP
Alternative Names: K-103-IP; K-103-PALatest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Kowa Pharmaceutical
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute pain; Inflammation
Most Recent Events
- 26 Sep 2019 Discontinued - Phase-III for Acute pain in China (Topical)
- 26 Sep 2019 Discontinued - Phase-III for Acute pain in USA (Topical)
- 26 Sep 2019 Discontinued - Phase-III for Inflammation in USA (Topical)